Xinying Yu1, Sanne N van Munster2, Yueming Zhang1, Liyan Xue3, David E Fleischer4, Bas L A M Weusten5, Ning Lu3, Sanford S M Dawsey6, Jacques J G H M Bergman2, Guiqi Wang1. 1. Department of Endoscopy, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China. 2. Department of Gastroenterology & Hepatology, Academic Medical Center, Amsterdam, the Netherlands. 3. Department of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China. 4. Department of Gastroenterology & Hepatology, Mayo Clinic, Scottsdale, Arizona, USA. 5. Department of Gastroenterology & Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Gastroenterology & Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands. 6. Department of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Abstract
BACKGROUND AND AIMS: Radiofrequency ablation (RFA) is an accepted treatment for flat Barrett's neoplasia. Less is known about RFA for esophageal squamous cell neoplasia (ESCN). Our group has reported several prospective studies of RFA for ESCN in China with promising results through 12 months of follow-up. In this cohort study we aimed to evaluate longer term outcomes after RFA for ESCN. METHODS: Patients with flat unstained lesions (USLs) on Lugol's endoscopy containing moderate-/high-grade intraepithelial neoplasia (MGIN/HGIN) or mucosal cancer were treated with RFA every 3 months until complete remission (CR; no MGIN or a worse histologic grade). Patients with CR at 12 months (CR12) were included for follow-up and underwent annual Lugol's endoscopy with biopsy sampling and re-RFA for flat USLs. The clinical course of patients with persistent ESCN at 12 months (treatment failures) is also reported. RESULTS: Among the 78 patients in CR12, 67 (86%) had sustained CR during a median of 48 months (interquartile range, 48-48) of follow-up and 5 endoscopies (interquartile range, 4-6). Recurrence occurred in 7 of 78 patients (9%; MGIN, n = 6; HGIN, n = 1); all lesions were managed with RFA. Four other patients (5%) had progression (to HGIN, n = 1; submucosal esophageal squamous cell carcinoma, n = 3). During follow-up protocol violations occurred in 46 of 78 patients (59%). Of the 12 treatment failures, progression occurred in 6. Overall, 2 patients developed subepithelial disease that was not visible after Lugol's endoscopy. Based on post-hoc analysis, the pink-color sign at baseline (a pink color change after Lugol's endoscopy) significantly predicted failure after RFA. CONCLUSIONS: RFA is relatively easy to apply and can efficiently treat large areas with ESCN. Despite protocol violations that may have interfered with the efficacy of RFA in 59% of patients, most patients with CR12 had sustained CR during follow-up. However, some patients progressed to advanced disease and 2 developed subepithelial disease, not visible after Lugol's endoscopy. Based on currently available data, we advise the restriction of the use of RFA for flat MGIN and HGIN without the pink-color sign on Lugol's chromoendoscopy. (Clinical trial registration number: NCT02047305.).
BACKGROUND AND AIMS: Radiofrequency ablation (RFA) is an accepted treatment for flat Barrett's neoplasia. Less is known about RFA for esophageal squamous cell neoplasia (ESCN). Our group has reported several prospective studies of RFA for ESCN in China with promising results through 12 months of follow-up. In this cohort study we aimed to evaluate longer term outcomes after RFA for ESCN. METHODS:Patients with flat unstained lesions (USLs) on Lugol's endoscopy containing moderate-/high-grade intraepithelial neoplasia (MGIN/HGIN) or mucosal cancer were treated with RFA every 3 months until complete remission (CR; no MGIN or a worse histologic grade). Patients with CR at 12 months (CR12) were included for follow-up and underwent annual Lugol's endoscopy with biopsy sampling and re-RFA for flat USLs. The clinical course of patients with persistent ESCN at 12 months (treatment failures) is also reported. RESULTS: Among the 78 patients in CR12, 67 (86%) had sustained CR during a median of 48 months (interquartile range, 48-48) of follow-up and 5 endoscopies (interquartile range, 4-6). Recurrence occurred in 7 of 78 patients (9%; MGIN, n = 6; HGIN, n = 1); all lesions were managed with RFA. Four other patients (5%) had progression (to HGIN, n = 1; submucosal esophageal squamous cell carcinoma, n = 3). During follow-up protocol violations occurred in 46 of 78 patients (59%). Of the 12 treatment failures, progression occurred in 6. Overall, 2 patients developed subepithelial disease that was not visible after Lugol's endoscopy. Based on post-hoc analysis, the pink-color sign at baseline (a pink color change after Lugol's endoscopy) significantly predicted failure after RFA. CONCLUSIONS: RFA is relatively easy to apply and can efficiently treat large areas with ESCN. Despite protocol violations that may have interfered with the efficacy of RFA in 59% of patients, most patients with CR12 had sustained CR during follow-up. However, some patients progressed to advanced disease and 2 developed subepithelial disease, not visible after Lugol's endoscopy. Based on currently available data, we advise the restriction of the use of RFA for flat MGIN and HGIN without the pink-color sign on Lugol's chromoendoscopy. (Clinical trial registration number: NCT02047305.).
Authors: F G van Vilsteren; L Alvarez Herrero; R E Pouw; F J ten Kate; M Visser; C A Seldenrijk; M I van Berge Henegouwen; B L Weusten; J J Bergman Journal: Endoscopy Date: 2011-03-31 Impact factor: 10.093
Authors: Y Tajima; Y Nakanishi; Y Tachimori; H Kato; H Watanabe; H Yamaguchi; K Yoshimura; M Kusano; T Shimoda Journal: Cancer Date: 2000-07-15 Impact factor: 6.860
Authors: Leandi Krüger; Liara M Gonzalez; Tiffany A Pridgen; Shannon J McCall; Richard J von Furstenberg; Ivan Harnden; Gwendolyn E Carnighan; Abigail M Cox; Anthony T Blikslager; Katherine S Garman Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-06-01 Impact factor: 4.052
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: B J Dunkin; J Martinez; P A Bejarano; C D Smith; K Chang; A S Livingstone; W S Melvin Journal: Surg Endosc Date: 2005-12-07 Impact factor: 3.453
Authors: Yan Ke; Sanne N van Munster; Liyan Xue; Shun He; Yueming Zhang; Lizhou Dou; Yong Liu; Xudong Liu; Yumeng Liu; Wei Li; Ning Lv; Sanford M Dawsey; Bas L A M Weusten; Jacques J G H M Bergman; Guiqi Wang Journal: Gastrointest Endosc Date: 2019-03-25 Impact factor: 9.427